Vyaire Medical Advances Surgical Sedation Safety with Novel Airway Technology for All Patient Risk Levels

The new SuperNO2VA™ Et mask establishes a new care paradigm for surgical options by maintaining an open airway and providing real-time exhaled carbon dioxide monitoring, decreasing sedation risk before, during and after surgery

Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the availability of SuperNO2VA™ Et, a mask that utilizes breakthrough technology to stent the airway open, thus avoiding airway collapse while accurately monitoring end tidal carbon dioxide (EtCO2), which is particularly important for high-risk patients.

Vyaire Medical notes it uniquely maintains airway patency while delivering precise and consistent oxygenation to patients during deep sedation procedures, helping reduce hypoxemia and hypoventilation. SuperNO2VA™ Et provides increased flexibility by providing continuous patient oxygenation before, during and after surgery, and transforms surgical practice by allowing more patients to have procedures under sedation.

“At Vyaire, we are committed to imagining new possibilities in the ways we can support breathing. SuperNO2VA™ Et does just that by removing some of the tangible risks of deep sedation through proprietary airway management technology and real-time clinical measurements to reduce complications,” said Gaurav Agarwal, chief executive officer, Vyaire. “Through this innovation, we envision reducing the need for general anesthesia and the associated complications, including extended procedure times, hospital stays and their burdens on healthcare systems.”

SuperNO2VA™ Et reduces hypoxemia by 75 percent and airway intervention by 65 percent compared to current standard of care.[i],[ii] It also allows for effective pre-oxygenation and rescue ventilation without the need for additional equipment, and eliminates the use and associated costs of a separate mask, endotracheal tube, laryngoscope and intubation.

“SuperNO2VA™ Et brings a new standard to the way surgeries can be performed for patients,” said Steven H. Cataldo, MD, director of anesthesiology at CareMount Medical and director of anesthesia services at Yorktown Center for Specialty Surgery. “With this technology, we are able to rethink how and where we operate, with decreased risks, procedure times and associated costs. Even high-risk patients can have reduced recovery times, providing them a safer and better overall care experience.”

“As the company inspired and empowered to elevate the quality of breathing, SuperNO2VA™ Et is an obvious yet critical piece of our innovation strategy and evolution,” said Agarwal. “We will continue to bring new-to-world technology to market to advance breathing solutions on behalf of customers and patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”